BC Extra | Nov 28, 2018
Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
BC Innovations | Jun 23, 2016
Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
BC Innovations | Apr 21, 2016
Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
BC Extra | Sep 5, 2014
Financial News

rEVO sets IPO terms

rEVO Biologics Inc. , a subsidiary of LFB S.A. (Les Ulis, France), set the terms for its IPO on NASDAQ. It plans to sell 3.6 million shares at $13-$15. LFB plans to purchase $10 million of...
BC Week In Review | Aug 4, 2014
Clinical News

ATryn: Phase III started

LFB’s rEVO Biologics Inc. subsidiary began the double-blind, placebo-controlled, U.S. Phase III PRESERVE-1 trial to evaluate ATryn in about 120 pregnant women. Patients will receive an initial 250 mg loading dose of ATryn followed by...
BC Extra | Jun 27, 2014
Financial News

rEVO files for IPO

rEVO Biologics Inc. , a subsidiary of LFB S.A. (Les Ulis, France), filed to raise up to $74.8 million in an IPO on NASDAQ underwritten by Piper Jaffray; Guggenheim Securities; Roth Capital Partners; and BTIG. rEVO...
BC Week In Review | Nov 15, 2010
Company News

GTC Biotherapeutics, Laboratoire francais deal

LFB will acquire and take private partner GTC for $0.30 per share, or about $21 million. The price is a 7% premium to GTC's close of $0.28 on Nov. 5, before the deal was announced...
BC Extra | Nov 9, 2010
Company News

LFB to acquire GTC

GTC Biotherapeutics Inc. (OTCBB:GTCB) said partner LFB S.A. (Les Ulis, France) agreed to take GTC private for $0.30 per share, or about $21 million. The price is a 7% premium to GTC's close of $0.28...
BC Week In Review | Oct 25, 2010
Company News

GTC Biotherapeutics, Laboratoire francais deal

Hematology company LFB proposed to acquire partner GTC for $0.28 per share, or about $17 million. The price is a 13% discount to GTC's close of $0.32 on Oct. 18, before the deal was announced....
BC Week In Review | Jul 19, 2010
Company News

GTC Biotherapeutics, Lundbeck deal

H. Lundbeck returned to GTC U.S. rights for hematology drug ATryn . The recombinant antithrombin is marketed in the U.S. to prevent peri-operative and peri-partum thromboembolic events in patients with hereditary antithrombin deficiency. Lundbeck, which gained...
Items per page:
1 - 10 of 106